The Product Development for Vaccines Advisory Committee (PDVAC) provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies. Its remit includes the prioritisation of target pathogens for vaccine and/or monoclonal antibody development and technology platforms, in addition to oversight of the development of preferred product characteristics (PPCs), technical/R&D roadmaps, full vaccine value assessments and consultations on product development pathways.
Presentations
Day 1
- Reprioritization within WHO IVB - K. O'Brien
- Gavi recalibration under 6.0 - M. Tufet
- Context and goals of this PDVAC meeting - E. Sparrow
- Update on IA2030 - K.P. Asante, M. Sheel, O. Wilson, and C. Imu-Jaja
- General updates - P. Gsell, M. Hasso-Agopsowicz, L. Wu, A. Ibarz, E. Sparrow
- Relevance of the clinical trial action plan to vaccines - V. Moorthy
- Inclusion of pregnant and lactating women in clinical trials - M. Penazzato and K. Mehring-Le Doare
- Shigella vaccines update - R. Kaminski, J. Platts-Mills, P. Pavlinac, E. Houpt, E. Tacket Rogawski McQuade, A. Wilder Smith
- Strategic framework for novel combination vaccines - W. Hausdorff, M. Hasso-Agopsowicz, P. J. Hotez, M. E. Bottazzi
Day 2
- New TB vaccines for adults and adolescents - B. Giersing, W. Hanekom, S. Den Boon, T. Prasad
- Adjuvants - N. Collin
- STI vaccines updates - S. Gotleib
- Global situation of Leishmaniasis - S. Jain
- Leishmaniasis vaccine development - P. Kaye
- CMV vaccines - S. Boppana
- Group B Strep vaccines - K. Mehring-Le Doare, M. Hindiyeh, A. Wilder Smith